Korea 2018 Review: Hopes And Worries Coexist In Pharma Sector
Executive Summary
As the year end approaches, Scrip wraps up what major events made headlines in the South Korean pharma/biotech sector in 2018.
| Table |
|---|
Advertisement
Related Content
Samsung BioLogics Vows Improved Management Transparency As Stock Resumes Trade
Roivant Buoys Anti-Infective Portfolio With Novel iNtRON Asset
Celltrion Hit By Truxima Price Cut, Temporary Utilization Rate Drop
Yuhan Strikes Long-Awaited Lung Cancer Deal Through Huge Janssen Alliance
Biosimilar Firms Main Beneficiaries Of Korea R&D Cost Accounting Changes?
Korea Toughens Corporate Disclosure Rules To Improve R&D Transparency
SK Acquires AMPAC, On Track To Meet Global Contract Manufacturing Ambitions
GC-Yuhan Orphan Alliance Signals Changing Korean Views On Open Innovation
Kolmar Korea Eyes Pharma Expansion Via CJ HealthCare Acquisition
Korea To Examine Companies' R&D-Related Accounting For Transparency
Topics
- Regions
- Asia Pacific
- Subjects
- Commercial
- Policy & Regulation
- Industries
- BioPharmaceutical
Related Companies
- Samsung BioLogics
- Samsung Bioepis Co. Ltd.
- Yuhan Corp.
- Janssen Biotech Inc.
- Roivant Sciences GMBH
- ABL Bio Corp.
- TRIGR Therapeutics Inc.
- Kolon Life Science Inc.
- Mitsubishi Tanabe Pharma Corp.
- Green Cross Corp.
- Celltrion Inc.
- Chong Kun Dang Pharmaceutical Corp.
- Alteogen Inc.
- LG Chem
- SK Biopharmaceuticals Co. Ltd.
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC124347
Ask The Analyst
Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
SC124347
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.